ASMB Financing

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

Published August 08, 2025 at 12:05 PM

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering (the “offering”) of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599. Each pre-funded warrant will have a nominal exercise price of $0.001 per share of common stock and will be immediately exercisable. Each accompanying Class A warrant will have an exercise price of $21.60 per share of common stoc

Related Questions

What is the total amount of capital raised after accounting for underwriting discounts and fees? How will the proceeds be allocated across the company's pipeline, especially the viral disease therapeutic programs? What is the implied valuation of Assembly Bio based on this pricing, and how does it compare to peer biotech companies? Are there any anti‑dilution or price‑adjustment provisions in the warrants that could affect future financing rounds? How does the $19.60 per share combined price compare to Assembly Bio's recent trading price and its historical financing pricing? What is the expected impact on the stock’s liquidity and bid‑ask spread once the offering is settled? What are the terms and expiry dates of the Class A and Class B warrants and how might they affect future dilution? How might this financing affect the company's cash runway and burn rate? How much dilution will the 5,591,840 common shares and the pre‑funded warrants cause for existing shareholders? Will the immediate exercisability of the pre‑funded warrants lead to a short‑term increase in the share count? What is the market’s likely reaction to the issuance of both common shares and multiple layers of warrants (Class A, Class B, pre‑funded) on the stock’s price volatility? What are the underwriting syndicate, fees, and any lock‑up or lock‑in provisions attached to this offering?